Loading organizations...
Ascent Biomedical Ventures is a New York City-based venture capital firm that invests in early-stage life sciences companies developing innovative medical devices and biopharmaceutical therapies. The firm focuses on the broader healthcare and biotechnology sectors, generating returns through equity investments that support emerging startups from their initial clinical development phases through final commercialization. Operating with a highly specialized core team of fewer than 10 employees, the firm has historically managed boutique investment vehicles, which includes raising over $50 million for its early venture funds. Ascent Biomedical Ventures has successfully backed several notable portfolio companies throughout its operational history, leading funding rounds for healthcare enterprises including NeoTract, Ocular Therapeutix, Medrobotics, and eCaring. The venture capital organization was originally founded in 2001 by managing partner Geoffrey W. Smith alongside a small group of specialized industry colleagues.
Key people at Ascent Biomedical Ventures.
Ascent Biomedical Ventures has 3 tracked investments across 3 companies. The latest tracked deal is $25.0M Series C in Xlumena in December 2013.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2013 | Xlumena | $25.0M Series C | Jason Hong | Aperture Venture Partners, Deerfield Management, Charter Life Sciences, Prism VentureWorks |
| Jul 1, 2012 | Coferon | $12.0M Series B | Hatteras Venture Partners, Ascent Biomedical Ventures, Michael Gutch | Digitalis Ventures |
| Jul 1, 2010 | Cara Therapeutics | $15.0M Series D | Martin Vogelbaum | Connecticut Innovations, Digitalis Ventures, Alta Partners, Devon Park Bioventures, Healthcare Private Equity, Mitsubishi Corporation, MVM Partners |
Ascent Biomedical Ventures (ABV) is a New York-based venture capital firm founded in 2004, specializing in seed and early-stage investments in biomedical technology companies.[1][2][3][4] The firm's mission centers on supporting innovations in medical devices, biopharmaceuticals, healthcare services, and information technology to advance medical science and improve patient care, primarily within the United States.[1][2][4] With 17-59 investments, 14 portfolio exits, and 2-3 funds managed, ABV has demonstrated a focused investment philosophy on high-potential healthcare startups, contributing to the biomedical ecosystem through capital and strategic backing.[1][4][5]
Ascent Biomedical Ventures was established in 2004 in New York City, with its headquarters at 142 West 57th Street, Suite 4A.[1][4] Key figures include Geoffrey W. Smith, the founder and general partner, leading a team of five members.[4] The firm has evolved with a consistent focus on seed and early-stage biomedical investments, managing closed funds since around 2007 and maintaining activity through investments like the 2020 Series D in Retrotope ($13.3M) and Seed VC in Base5 Genomics ($1.05M).[4][5] This trajectory reflects a steady commitment to the U.S. healthcare innovation landscape amid growing demand for biomedical advancements.[1][3]
Ascent Biomedical Ventures rides the wave of accelerating biomedical innovation, driven by trends in personalized medicine, advanced diagnostics, and digital health tools amid rising healthcare demands from aging populations and post-pandemic tech adoption.[1][2] Its timing aligns with a maturing U.S. venture ecosystem where early-stage biotech funding has surged, enabling ABV to back pivotal players like Retrotope and Base5 Genomics that address unmet needs in therapeutics and genomics.[4] By concentrating investments domestically, ABV influences the ecosystem through exits that validate models and recycle capital, strengthening networks for future healthcare breakthroughs.[1][4]
ABV's niche expertise positions it to capitalize on emerging trends like AI-driven drug discovery and next-gen medical devices, potentially expanding its portfolio amid projected biotech funding rebounds.[1][4] With a lean team and solid exit history, the firm could scale influence by deepening operating support for portfolio companies navigating regulatory hurdles. As biomedical tech integrates with broader health tech, ABV's early-stage focus will likely amplify its role in shaping patient-centric innovations, building on two decades of fostering U.S. leadership in medical advancement.[2][3][4]
Key people at Ascent Biomedical Ventures.
